Affiliation: University of Birmingham
- First report on an inotropic peptide activating tetrodotoxin-sensitive, "neuronal" sodium currents in the heartPaulus Kirchhof
From the Department of Cardiovascular Medicine P K, L F, S N, L F, Department of Pharmacology and Toxicology J K, J S S, F U M, W S, U K, and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease IfGH B S, E S B, Hospital of the University of Muenster, Muenster, Germany Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom P K, L F Technion Israel Institute of Technology, Haifa, Israel T T Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel T T, N N, E Z Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic J K Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I P E and Institute of Physiology I T K, T B
Circ Heart Fail 8:79-88. 2015..Here, we report the cardiac effects of a novel positive inotropic peptide isolated from the toxin of the Black Judean scorpion that activates neuronal tetrodotoxin-sensitive sodium channels...
- Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissuePeter C Kahr
Department of Cardiology and Angiology, University Hospital Munster, Munster, Germany
PLoS ONE 6:e26389. 2011..We therefore systematically studied the molecular composition of left and right atrial tissue in adult murine and human atria...
- Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)Paulus Kirchhof
University of Birmingham Centre for Cardiovascular Sciences and SWBH NHS Trust, City Hospital, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, Institute of Biomedical Research IBR 136, Birmingham B15 2TT, UK
Europace 16:6-14. 2014..We sought to describe the management of patients with atrial fibrillation (AF) in Europe after the release of the 2010 AF Guidelines of the European Society of Cardiology...
- Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention TrialPaulus Kirchhof
University of Birmingham Centre for Cardiovascular Sciences and SWBH NHS Trust, Birmingham, UK Department of Cardiovascular Medicine, University Hospital Munster, Munster, Germany Kompetenznetz Vorhofflimmern e V AFNET e V, c o University of Münster, Munster, Germany Electronic address
Am Heart J 166:442-8. 2013..Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions...
- Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conferencePaulus Kirchhof
Hospital of University of Münster, Munster, Germany
Thromb Haemost 106:1012-9. 2011..Risk factors and risk markers for AF, 2. Pathophysiological classification of AF, 3. Relevance of monitored AF duration for AF-related outcomes, and 4. Perspectives and needs for implementing better antithrombotic therapy...
- Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trialPaulus Kirchhof
Department of Cardiology and Angiology, Hospital of the University of Münster, Germany
Lancet 380:238-46. 2012..Therefore, we investigated whether short-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment...
- [Atrial fibrillation: current recommendations for diagnosis and treatment]P Kirchhof
Institute for Biomedical Research, University of Birmingham Centre for Cardiovascular Sciences and SWBH NHS Trust, B15 2TT Birmingham, United Kingdom
Internist (Berl) 54:583-95. 2013..The choice of the rhythm-control therapy should be made based on safety considerations. Whether achieving sinus rhythm beyond improvement of symptoms improves the prognosis of AF is tested in ongoing trials...
- Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisionsP Kirchhof
Department of Cardiology and Angiology, University Hospital Munster, Albert Schweitzer Straße 33, D 48149 Munster, Germany
Thromb Haemost 105:1010-23. 2011..Inpatients receive more rhythm control therapy. Adequate antithrombotic therapy is more often administered in specialist (cardiologist) centres...